Protective effect of erythropoietin and its carbamylated derivative in experimental cisplatin peripheral neurotoxicity

被引:73
作者
Bianchi, R
Brines, M
Lauria, G
Savino, C
Gilardini, A
Nicolini, G
Rodriguez-Menendez, V
Oggioni, N
Canta, A
Penza, P
Lombardi, R
Minoia, C
Ronchi, A
Cerami, A
Ghezzi, P
Cavaletti, G
机构
[1] Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy
[2] Besta Natl Neurol Inst, Milan, Italy
[3] Kenneth S Warren Inst, Kitchawan, NY USA
[4] Univ Milano Bicocca, Monza, Italy
[5] Maugeri Fdn, Pavia, Italy
关键词
D O I
10.1158/1078-0432.CCR-05-2177
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Antineoplastic drugs, such as cisplatin (CDDP), are severely neurotoxic, causing disabling peripheral neuropathies with clinical signs known as chemotherapy-induced peripheral neurotoxicity. Cotreatment with neuroprotective agents and CDDP has been proposed for preventing or reversing the neuropathy. Erythropoietin given systemically has a wide range of neuroprotective actions in animal models of central and peripheral nervous system damage. However, the erythropoietic action is a potential cause of side effects if erythropoietin is used for neuroprotection. We have successfully identified derivatives of erythropoietin, including carbamylated erythropoietin, which do not raise the hematocrit but retain the neuroprotective action exerted by erythropoietin. Experimental Design: We have developed previously an experimental chemotherapy-induced peripheral neurotoxicity that closely resembles CDDP neurotoxicity in humans. The present study compared the effects of erythropoietin and carbamylated erythropoietin (50 mu g/kg/d thrice weekly) on CDDP (2 mg/kg/d i.p. twice weekly for 4 weeks) neurotoxicity in vivo. Results: CDDP given to Wistar rats significantly lowered their growth rate (P < 0.05), with slower sensory nerve conduction velocity (P < 0.001) and reduced intraepidermal nerve fibers density (P < 0.001 versus controls). Coadministration of CDDP and erythropoietin or carbamylated erythropoietin partially but significantly prevented the sensory nerve conduction velocity reduction. Both molecules preserved intraepidermal nerve fiber density, thus confirming their neuroprotective effect at the pathologic level. The protective effects were not associated with any difference in platinum concentration in dorsal root ganglia, sciatic nerve, or kidney specimens. Conclusions: These results widen the spectrum of possible use of erythropoietin and carbamylated erythropoietin as neuroprotectant drugs, strongly supporting their effectiveness.
引用
收藏
页码:2607 / 2612
页数:6
相关论文
共 49 条
[1]   NERVE GROWTH-FACTOR PREVENTS TOXIC NEUROPATHY IN MICE [J].
APFEL, SC ;
LIPTON, RB ;
AREZZO, JC ;
KESSLER, JA .
ANNALS OF NEUROLOGY, 1991, 29 (01) :87-90
[2]   NERVE GROWTH-FACTOR PREVENTS EXPERIMENTAL CISPLATIN NEUROPATHY [J].
APFEL, SC ;
AREZZO, JC ;
LIPSON, L ;
KESSLER, JA .
ANNALS OF NEUROLOGY, 1992, 31 (01) :76-80
[3]   Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy [J].
Barajon, I ;
Bersani, M ;
Quartu, M ;
DelFiacco, M ;
Cavaletti, G ;
Holst, JJ ;
Tredici, G .
EXPERIMENTAL NEUROLOGY, 1996, 138 (01) :93-104
[4]   Erythropoietin both protects from and reverses experimental diabetic neuropathy [J].
Bianchi, R ;
Buyukakilli, B ;
Brines, M ;
Savino, C ;
Cavaletti, G ;
Oggioni, N ;
Lauria, G ;
Borgna, M ;
Lombardi, R ;
Cimen, B ;
Comelekoglu, U ;
Kanik, A ;
Tataroglu, C ;
Cerami, A ;
Ghezzi, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (03) :823-828
[5]   EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer [J].
Bokemeyer, C ;
Aapro, MS ;
Courdi, A ;
Foubert, J ;
Link, H ;
Österborg, A ;
Repetto, L ;
Soubeyran, P .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (15) :2201-2216
[6]   Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor [J].
Brines, M ;
Grasso, G ;
Fiordaliso, F ;
Sfacteria, A ;
Ghezzi, P ;
Fratelli, M ;
Latini, R ;
Xie, QW ;
Smart, J ;
Su-Rick, CJ ;
Pobre, E ;
Diaz, D ;
Gomez, D ;
Hand, C ;
Coleman, T ;
Cerami, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (41) :14907-14912
[7]   Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury [J].
Brines, ML ;
Ghezzi, P ;
Keenan, S ;
Agnello, D ;
de Lanerolle, NC ;
Cerami, C ;
Itri, LM ;
Cerami, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (19) :10526-10531
[8]   The pleiotropic effects of erythropoietin in the central nervous system [J].
Buemi, M ;
Cavallaro, E ;
Floccari, E ;
Sturiale, A ;
Aloisi, C ;
Trimarchi, M ;
Corica, F ;
Frisina, N .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2003, 62 (03) :228-236
[9]   Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury [J].
Campana, WM ;
Myers, RR .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2003, 18 (06) :1497-1506
[10]   Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury [J].
Campana, WM ;
Myers, RR .
FASEB JOURNAL, 2001, 15 (08) :1804-+